La vendita allo scoperto per Clene dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Clene. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Clene (NASDAQ:CLNN) Azioni, Report sulle vendite allo scoperto

CLENE INC

Clene

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.

CenterPoint Energy today announced that Jesus Soto, Jr, a well-respected, energy industry executive with deep Texas roots will join the company as Executive Vice President and Chief Operating Officer. Soto will oversee the company's Electric Operations, Gas Operations, Safety, Supply Chain, and Customer Care functions, across all the states that CenterPoint serves. He will join the company on Aug. 11, 2025, and report to President &amp; CEO Jason Wells.

News

Management

CenterPoint Energy Appoints Jesus Soto Jr As EVP And COO, Effective Aug. 11, 2025

Alkermes plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) on Monday released topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study evaluating alixorexton in patients <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">with narcolepsy type 1 (NT1)</a>.
Narcolepsy is a chronic neurological disorder that disrupts the body&#8217;s ability to regulate sleep-wake cycles. It&#8217;s characterized by excessive daytime sleepiness and sudden, uncontrollable sleep attacks.
Alixorexton, formerly ALKS 2680, is an investigational, oral orexin 2 receptor (OX2R) agonist in phase 2 development as a once-daily treatment for NT1, narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43826737/harmony-biosciences-stock-falls-on-fda-setback-for-pitolisant-in-sleeping-disorder" rel="noreferrer noopener">Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder</a>
In Vibrance-1, alixorexton met the primary endpoint across all doses tested, demonstrating statistically significant, clinically meaningful, and dose-dependent improvements in wakefulness on the Maintenance of Wakefulness Test (MWT) from <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46513802/alkermes-announces-positive-topline-results-from-vibrance-1-phase-2-study-of-once-daily-alixorexto" rel="noreferrer noopener">baseline compared to placebo</a>.
In addition to achieving normative wakefulness across all dose groups on the MWT (mean sleep latency >20 minutes), once-daily alixorexton demonstrated robust and clinically meaningful improvements compared to placebo on patient-reported outcomes related to excessive daytime sleepiness and other key symptoms such as fatigue and cognition. 
Alixorexton was generally well tolerated at all doses tested. These data support rapid initiation of a global phase 3 program of alixorexton in patients with NT1.
<h2 class="wp-block-heading">Key Secondary Endpoints</h2>
Epworth Sleepiness Scale (ESS): At all doses tested, alixorexton drove statistically significant and clinically meaningful improvements from baseline in excessive daytime sleepiness compared to placebo on the Epworth Sleepiness Scale at week six (p&lt;0.0001 at all doses).
Weekly Cataplexy Rates (WCR): Alixorexton numerically improved weekly cataplexy rates across all doses compared to placebo at week six and achieved statistical significance at the 6 mg dose (p=0.005).
Alixorexton demonstrated consistent and clinically meaningful improvements across several patient-reported outcome measures of symptoms important to patients, including:
Narcolepsy Severity Scale (NSS): Across all doses tested, alixorexton demonstrated clinically meaningful improvements from baseline in narcolepsy symptom severity as compared to placebo at week six (p&lt;0.001 at all doses).
British Columbia Cognitive Complaints Inventory (BC-CCI): Across all doses tested, alixorexton demonstrated clinically meaningful improvements from baseline in cognitive complaints compared to placebo at week six (p&lt;0.0001 at all doses).
PROMIS (Patient-Reported Outcomes Measurement Information System)-Fatigue: Across all doses tested, alixorexton demonstrated clinically meaningful improvements from baseline in fatigue as compared to placebo at week six (p&lt;0.01 at all doses).
Alixorexton was generally well tolerated across all doses tested in the randomized double-blind period of the Vibrance-1 study.
No treatment-emergent serious adverse events (TEAEs) were reported. Most TEAEs were mild to moderate in severity and generally consistent with the events observed across the Alixorexton phase 1 program in healthy volunteers and patients.
No treatment-related safety signals were observed in hepatic and renal parameters, vital signs, or ophthalmic exams.
Vibrance-2 and Vibrance-3, phase 2 studies evaluating the safety and efficacy of alixorexton in adults with NT2 and IH, respectively, are ongoing.
In April 2024, Alkermes revealed topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a phase 1b, proof-of-concept study evaluating&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38170051/alkermes-sleeping-disorder-studies-data-look-excellent-analyst-says" rel="noreferrer noopener">ALKS 2680 for narcolepsy</a>.&nbsp;
ALKS 2680 data demonstrated clinically meaningful and statistically significant improvements from baseline in mean sleep latency on the Maintenance of Wakefulness Test compared to placebo at all doses tested.&nbsp;
Price Action: ALKS stock is trading lower by 7.24% to $27.11 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/commodities/25/07/46514212/china-led-rally-sends-iron-ore-over-100-despite-looming-oversupply" target="_blank" rel="noreferrer noopener">China-Led Rally Sends Iron Ore Over $100 Despite Looming Oversupply</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

Movers

General

ALKS

Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study

D. Boral Capital analyst Jason Kolbert maintains CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) with a Buy and maintains $10 price target.

Price Target

Analyst Ratings

CTSO

D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target

D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) with a Buy and maintains $16 price target.

BMEA

D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $16 Price Target

<a href="https://www.cnbc.com/2025/07/21/jpmorgan-quantum-computing-leadership-state-street-exec.html" title="https://www.cnbc.com/2025/07/21/jpmorgan-quantum-computing-leadership-state-street-exec.html">https://www.cnbc.com/2025/07/21/jpmorgan-quantum-computing-leadership-state-street-exec.html</a>

'JPMorgan Chase Overhauls Quantum Computing Leadership, Poaches State Street Executive; Marco Pistoia, Who Became Head Of JPMorgan's Applied Research Group In 2020, Has Recently Left The Bank' - CNBC

The altcoin rally may only be getting started and follows the signing of the GENIUS Act, the most significant U.S. crypto legislation to date, ushering in <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46508890/trump-signs-genius-act-ending-biden-era-crypto-probes-and-backing-industry-titans">structural clarity for digital assets</a>.
Speaking with Benzinga, Illia Otychenko, Lead Analyst at CEX.IO, identified three critical technical and on-chain signals driving the breakout.
"Net Taker Volume flipped positive, showing renewed buy-side aggression after months of seller dominance," Otychenko said. 
He also noted that long-term holders are moving from accumulation to distribution, a phase that has historically coincided with Bitcoin's steepest rallies.
Combined with a recent Golden Cross, where the 50-day moving average crossed above the 200-day, Otychenko said Bitcoin could see a short-term rise to $132,000 and as high as $170,000 by the end of Q3. 
These bullish indicators are consistent with earlier rally phases in the current cycle, including a 103% surge to $108,000 in January 2025.
Iliya Kalchev, analyst at Nexo Dispatch, echoed the sentiment, highlighting a sharp rotation from Bitcoin to Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) and select altcoins. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46524833/ethereum-is-at-the-forefront-of-the-financial-services-revolution-bernstein-says">Ethereum Is At The Forefront Of The Financial Services Revolution, Bernstein Says</a>
"Ethereum is leading the charge, now at just under $3,800, up 1.6x since April," Kalchev said, adding that new institutional bids, like SharpLink Gaming's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) $6 billion ETH proposal, reinforce the asset's growing appeal as a balance sheet asset.
The GENIUS Act, signed into law last Friday, resolves longstanding regulatory friction in the U.S. 
It establishes clear rules for stablecoins, distinguishes asset classifications, and protects developers, prompting a broader investor reassessment of crypto exposure. 
The timing coincides with declining Bitcoin dominance and growing appetite for higher-beta assets such as ENA, XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>), and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>).
The shifting capital landscape has sent ENA up 40% in a week, XRP past $3.50, and SOL near $191, with DOGE showing renewed strength in technical patterns and derivatives activity.
Cooper Research forecasts Bitcoin may hit $150,000 by October, buoyed by continued ETF inflows and macro tailwinds. 
Ethereum, meanwhile, could extend gains with analysts like Tom Lee of Fundstrat citing targets of $4,000 in the near term and $15,000 longer term.
At the same time, macro developments loom, including preliminary U.S. GDP data and flash PMIs, but traders remain focused on crypto's new regulatory footing and asset rotation themes.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46520495/strategy-buys-6220-btc-boosts-bitcoin-war-chest-to-607770">Strategy Buys 6,220 BTC, Boosts Bitcoin War Chest To 607,770</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ENA

$ETH

$SOL

$XRP

SBET

Ethereum, XRP, SOL Surge After GENIUS Act: What's Driving The Altcoin Rally?

<a href="https://www.bloomberg.com/news/articles/2025-07-21/fidji-simo-lays-out-vision-as-openai-ceo-of-applications-ahead-of-august-start">https://www.bloomberg.com/news/articles/2025-07-21/fidji-simo-lays-out-vision-as-openai-ceo-of-applications-ahead-of-august-start</a>

MSFT

'Fidji Simo Lays Out Vision As OpenAI CEO of Applications Ahead of August Start'- Bloomberg

Telsey Advisory Group analyst Sarang Vora maintains Coursera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) with a Outperform and maintains $12 price target.

COUR

Telsey Advisory Group Maintains Outperform on Coursera, Maintains $12 Price Target

A rare warning signal just reappeared in the market — and the last time it showed up, <a href="https://www.benzinga.com/topic/s-p-500">the S&amp;P 500 index</a> plunged more than 20% in a matter of weeks.
According to the <a href="https://www.aaii.com/latest/article/316918-aaii-sentiment-survey-pessimism-pushes-through">latest</a> AAII Sentiment Survey, the bull-bear spread has collapsed to just 0.3%, the lowest since September 2022 — right before the S&amp;P logged its steepest drop since the 2008 financial crisis.
That signal comes as bullish sentiment drops to 39.3% and bearish sentiment surges to 39.0%, a near-perfect split that reflects deep investor indecision. Neutral sentiment, meanwhile, remains depressed at 21.8%, well below its historical average of 31.5%. This extreme polarization often sets the stage for outsized volatility.
Read Also: <a href="https://www.benzinga.com/crypto/25/07/46526038/trump-bitcoin-gold-401k-retirement-funds-performance">Trump Wants Bitcoin And Gold In Your 401(k)—And The Math Backs Him Up</a>
<h2 class="wp-block-heading">Sentiment Deadlock Often Precedes Big Market Moves</h2>
When investors are evenly split, the market tends to lose its anchor. With neither bulls nor bears clearly in control, the S&amp;P 500 becomes vulnerable to fast and sharp moves. The last time the bull-bear spread hit such lows — in late 2022 — the index went on to suffer its worst annual loss since the global financial crisis.
Though current market levels remain elevated, the psychological backdrop has shifted. Investors are taking sides, not sitting out, and that often signals that something's about to give.
<h2 class="wp-block-heading">Positioning Around The Uncertainty</h2>
For those looking to stay invested while managing risk, ETFs such as SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Vanguard Total Stock Market ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTI#NYSE">VTI</a>) offer broad exposure. If tech optimism remains intact, Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) provides leverage to growth themes.
For downside protection, low-volatility plays such as iShares MSCI USA Min Vol Factor ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/USMV#BATS">USMV</a>) or dividend-focused funds like Vanguard Dividend Appreciation Index Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIG#NYSE">VIG</a>) can help buffer shocks. Tactical investors expecting short-term pullbacks may also consider ProShares Short S&amp;P500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SH#NYSE">SH</a>) as a hedge.
Whether the signal leads to a repeat of 2022 or not, history suggests it's not one to ignore.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/07/46524500/wall-street-meets-web3-fintech-etfs-spy-voo-to-get-jack-dorsey-upgrade-as-block-joins-sp-500">Wall Street Meets Web3: Fintech ETFs, SPY, VOO To Get Jack Dorsey Upgrade As Block Joins S&amp;P 500</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Macro Economic Events

Broad U.S. Equity ETFs

Economics

Trading Ideas

ETFs

USMV

The Last Time This Warning Flashed, S&P 500 Crashed The Most Since 2008

WIIM

MFH stock has given up its prior gain. Mercurity Fintech shares were trading higher after the company announced it has entered into a $200 million equity line of credit agreement to launch a Solana-based treasury strategy.

Market Summary

Benzinga Market Summary: S&P Rises Amid Tech Strength, Gold Gains On Weaker Dollar, Cybersecurity Stocks Gain Amid SharePoint Hack

<a href="https://www.hhs.gov/press-room/hrsa-to-reform-organ-transplant-system.html#:~:text=It%20found%3A,serious%20ethical%20and%20legal%20questions" title="https://www.hhs.gov/press-room/hrsa-to-reform-organ-transplant-system.html#:~:text=It%20found%3A,serious%20ethical%20and%20legal%20questions">https://www.hhs.gov/press-room/hrsa-to-reform-organ-transplant-system.html#:~:text=It%20found%3A,serious%20ethical%20and%20legal%20questions</a>.

CDNA

TMDX

UTHR

'HHS Finds Systemic Disregard for Sanctity of Life in Organ Transplant System; To Begin Reforming Organ Transplant System; HRSA's Independent Investigation Revealed Clear Negligence After Previous OPTN Board Claimed To Find No Major Concerns In Internal Review'

CRWD

FTNT

PANW

SNOW

Shares of several cybersecurity-related stocks are trading higher amid a cyber attack on Microsoft's SharePoint servers.

Roth Capital analyst Rohit Kulkarni maintains Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Neutral and raises the price target from $130 to $145.

RDDT

Roth Capital Maintains Neutral on Reddit, Raises Price Target to $145

CGAU

PAAS

RGLD

SSRM

USAU

Shares of precious metal-related stocks are trading higher amid tariff uncertainty, which has weakened the US dollar and bond yields.

Piper Sandler analyst Crispin Love maintains Virtus Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTS#NYSE">VRTS</a>) with a Overweight and raises the price target from $211 to $234.

VRTS

Piper Sandler Maintains Overweight on Virtus Inv, Raises Price Target to $234

Global

Reuters Cites UK Government Saying Memorandum Of Understanding Between The UK And OpenAI On AI Opportunities; OpenAI May Also Explore Developing, AI-Enabled R&D Infrastructure In The UK; OpenAI And DSIT To Collaborate To Identify Opportunities For How Advanced AI Models Can Be Deployed Throughout Government & Private Sector

Shares of Galaxy Digital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXY#NASDAQ">GLXY</a>) are trading higher Monday after the company <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46523447/galaxy-digital-stock-is-moving-higher-monday-whats-going-on">announced a partnership with K Wave Media</a>.
What To Know: The collaboration is intended to advance Bitcoin treasury strategies and provide access to greater institutional capital. The move positions Galaxy to strengthen its presence in the digital asset space through expanded financial partnerships.
The rally also followed a detailed valuation update from Piper Sandler analysts Patrick Moley and Will Copps, who maintained an Overweight rating on Galaxy shares with a $36 price target. In their note, the analysts provided a deep dive into the sum-of-the-parts valuation of Galaxy's business and evaluated multiple scenarios tied to the company's Helios data center operations in Texas.
The report highlighted that if Galaxy secures approval for its full 2.5 gigawatts of planned power capacity at the Helios site and contracts it at economics similar to its existing 600-megawatt deal with CoreWeave, the stock could be worth up to $43 per share. 
The valuation for the Helios data center business alone was estimated between $9.35 and $28.72 per share, depending on the total contracted capacity. Galaxy currently has approval for 800 megawatts of power at Helios and is awaiting regulatory clearance for an additional 1.7 gigawatts from ERCOT.
The analysts noted that the implied valuation range for Galaxy shares spans from $24 to $43, reflecting potential downside of around 13% and upside of about 59% based on recent trading levels. They also cautioned that risks include regulatory changes in the cryptocurrency market, Bitcoin price volatility, energy costs, and operational risks related to mining infrastructure.
Galaxy operates as a diversified digital asset firm, providing services across investment banking, trading, prime brokerage, and asset management. The company's stock moved higher on a mix of the strategic partnership announcement and the renewed analyst focus on its data center expansion potential.
GLXY Price Action: Galaxy Digital shares were up 8.51% at $29.44 at the time of writing, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/07/46526172/wall-street-today-gold-bessent-fed-sp500-monday-markets">Wall Street Extends Records, Gold Rallies To $3,400: What&#8217;s Moving Markets Monday?</a></li>
</ul>
Image Via Shutterstock.

GLXY

Galaxy Digital Shares Rise On Bitcoin Treasury Partnership And Analyst Valuation Outlook

Wayfair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) is gearing up to release its second-quarter earnings before the market opens on August 4, with expectations of surpassing Street estimates for both sales and profitability.
On Monday, Bank of America Securities analyst Curtis Nagle reiterated a <a target="_blank" href="https://www.benzinga.com/quote/W/analyst-ratings" rel="noreferrer noopener">Neutral rating</a> on Wayfair, setting a price forecast of $60. Nagle&#8217;s projection of $3.15 billion in second-quarter sales surpasses the Street&#8217;s consensus of $3.12 billion.
This more bullish outlook is attributed to stronger-than-expected industry trends, increased inventory availability driven by higher utilization of Wayfair&#8217;s CastleGate system, and effective vendor-funded promotions.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45147261/whats-going-on-with-wayfair-stock-on-thursday" rel="noreferrer noopener">Wayfair Stock Rises After Surprise Q1 Profit and Higher Sales Beat Expectations</a>
The analyst&#8217;s EBITDA estimate of $153 million also exceeds the Street&#8217;s $146 million, fueled by expectations of higher gross profit dollars due to greater flow-through and leverage from Selling, Operations, Technology, General &amp; Administrative expenses, particularly from a right-sizing of the company&#8217;s tech headcount.
Supporting these positive trends, Bank of America&#8217;s aggregated credit and debit card data indicated a slight improvement in online furniture spending, which declined by 0.8% year-over-year in the second quarter, compared to a 1.6% decline in the first quarter.
Nagle suggests that these improving trends could signify a pull-forward in demand and increased promotional spending, although this might potentially come at the expense of industry sales later in the year.
He further noted that accelerating web and app trends suggest Wayfair is continuing to gain market share, driven by better product availability and vendor-funded promotions. Consequently, Nagle raised his second-quarter sales estimate by 1% to $3.15 billion and his EBITDA estimate by 2%.
Looking ahead to the third quarter, Nagle also increased his sales estimate by 1% to $2.86 billion, which aligns closely with the Street&#8217;s estimate of $2.87 billion.
This adjustment reflects the better-than-expected performance of consumer spending and the broader furnishings category. Furthermore, concerns regarding tariffs appear to be easing following Vietnam&#8217;s trade deal, despite an August 1 deadline.
The extended Black Friday in July event also indicates a healthy supply on the site, likely as vendors increasingly leverage CastleGate. Nagle sees this event as an additional opportunity for Wayfair to drive incremental sales. However, he maintained his fourth-quarter estimates, primarily due to tougher year-over-year comparisons.
While tariff concerns are abating, they remain a significant point of discussion for Wayfair. As such, topics on the upcoming earnings call are likely to revolve around the potential impact of tariffs on second-half 2025 trends and how vendors are navigating these challenges, particularly through CastleGate, vendor-funded promotions, and renegotiations. Nagle observed that the current share price already reflects the potential upside from easing tariffs and healthy supply trends.
Price Action: Wayfair shares are trading lower by 1.51% to $55.59 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/social-media/25/04/44747892/amazon-wayfair-pinterest-win-analyst-backing-due-to-tariff-pause-supply-chain-relief-discretionary-spend-recovery" target="_blank" rel="noreferrer noopener">Amazon, Wayfair, Pinterest Win Analyst Backing Due To Tariff Pause, Supply Chain Relief, Discretionary Spend Recovery</a></li>
</ul>
Image via Shutterstock

Reiteration

Wayfair Poised For Q2 Sales Beat On Strong Inventory, Vendor Promotions

<h3>Gainers</h3>
<ul>
<li>ATA Creativity Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AACG#NASDAQ">AACG</a>) stock rose 28.0% to $1.05 during Monday's regular session. The market value of their outstanding shares is at $25.8 million. </li>
<li>Netclass Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTCL#NASDAQ">NTCL</a>) shares increased by 20.66% to $1.81. The market value of their outstanding shares is at $26.7 million. </li>
<li>XWELL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XWEL#NASDAQ">XWEL</a>) stock rose 20.05% to $1.29. The market value of their outstanding shares is at $5.6 million. </li>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) shares increased by 14.38% to $0.15. The company's market cap stands at $6.4 million. </li>
<li>Perfect Moment (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PMNT#AMEX">PMNT</a>) stock rose 13.95% to $0.37. </li>
<li>MaxsMaking (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMK#NASDAQ">MAMK</a>) stock increased by 12.64% to $2.85. The company's market cap stands at $42.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Barnes &amp; Noble Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNED#NYSE">BNED</a>) shares declined by 18.8% to $9.12 during Monday's regular session. The company's market cap stands at $382.4 million. </li>
<li>QuantumScape (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) stock fell 13.91% to $12.6. The company's market cap stands at $8.1 billion. </li>
<li>Jowell Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JWEL#NASDAQ">JWEL</a>) stock declined by 13.68% to $2.07. The market value of their outstanding shares is at $5.2 million. </li>
<li>Chijet Motor Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJET#NASDAQ">CJET</a>) shares declined by 13.41% to $2.26. The company's market cap stands at $80.6 million. </li>
<li>Massimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMO#NASDAQ">MAMO</a>) shares fell 10.69% to $2.5. The company's market cap stands at $116.2 million. </li>
<li>Mullen Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) stock decreased by 10.42% to $0.08. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AACG

BNED

CJET

JWEL

MAMK

MAMO

MULN

NTCL

PMNT

XWEL

12 Consumer Discretionary Stocks Moving In Monday's Intraday Session

Press Releases

Clene to Present at the Emerging Growth Conference

Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream

Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

Earnings

Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream

Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

Events

Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings

Presenting on Emerging Growth Conference 84 Day 1 on July 16; Register to live stream

Presenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live stream

Comments

Clene

Vendite allo scoperto

Clene (NASDAQ:CLNN) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO